Our study aimed to evaluate the efficacy, that is, progression‐free survival (PFS), overall survival (OS) and objective response rate (ORR) of anti‐PD‐1 monotherapy and BRAF/MEK inhibition therapy in patients with BRAF‐mutated metastatic melanoma. This evidence concerns the gene BRAF and metastatic melanoma.